Amgen Suspends Trial of Cancer Drug
Stock quotes in this article:
AMGN
THOUSAND OAKS, Calif. -- Biotech drugmaker Amgen (AMGN Quote) and a unit of Japanese drugmaker Takeda Pharmaceutical suspended enrollment in a late-stage trial of a cancer drug after patients on the drug died more often than those on placebo.
The trial tests an experimental drug called motesanib in combination with paclitaxel and carboplatin to treat a type of lung cancer. Early data showed higher early mortality rates among patients receiving motesanib than among patients receiving a placebo, or dummy medication. The trial's data-monitoring committee also recommended that patients with squamous non-small-cell lung cancer on motesanib stop taking the drug. However, they did not recommend stopping the treatment for patients with the non-squamous version of the disease. The patients with the squamous form of the disease had a higher incidence of hemoptysis, or coughing up blood. A safety committee will review new data from the study in three months, the companies said.- Loading Comments...
- Loading Comments...
Recent Comments
Featured Photo Galleries
| Dow Jones | S&P 500 | NASDAQ | 10-Year Note | |
|---|---|---|---|---|
| 10,471.58 | 1,108.86 | 2,175.81 | 32.90 |
Oil *
78.99
|
|
UP
126.74
|
UP
13.23
|
UP
31.21
|
UP
0.15
|
10 Yr
3.29%
SPDR Gold
117.38
|
|
+1.23%
|
+1.21%
|
+1.46%
|
+0.46%
|
Data delayed 20 minutes |














